Letters to the Editor

Daunorubicin-60 vs daunorubicin-90 vs idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience

Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Department of Internal Medicine and Division of Hematology
Division of Hematopathology
Division of Hematopathology
Department of Internal Medicine and Division of Hematology
Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN
Department of Internal Medicine and Division of Hematology
Haematologica Early view Jun 23, 2022 https://doi.org/10.3324/haematol.2022.281045